Clene Inc. (CLNN)
Nasdaq · Consumer Defensive · Packaged Foods
$3.91−4.17%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $55.6M
- 52-week range
- $3.25 – $13.50
- 52-week change
- −55.02%
- EPS (trailing)
- −$3.52
Fiscal year to Dec 2025
- Revenue
- $200K (−41.52%)
- Net income
- −$26.2M
- Operating margin
- −11541.5%
- Free cash flow
- −$18.6M
From the company’s annual report on SEC EDGAR.
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
Headquarters: Salt Lake City, United States · 76 employees · clene.com